IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α
- 1 March 1994
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 45 (3), 262-264
- https://doi.org/10.1002/ajh.2830450315
Abstract
A 69‐year‐old woman with IgE/K plasma cell leukemia (PCL) was treated with a sequential combination of VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α (IFNα). A complete remission was achieved for 14 months. Maintenance therapy with IFNα has continued for an additional 10 months. IgE PCL Is extremely rare. The biological characteristics of the myeloma cells, including surface marker, adhesion molecule, karyotype, DNA analysis, and the response to various cytokines, are presented.Keywords
This publication has 9 references indexed in Scilit:
- Ifosfamide in plasma cell leukemia: A report of two cases and review of the literatureAmerican Journal of Hematology, 1992
- Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myelomaBlood, 1992
- Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemiaAmerican Journal of Hematology, 1992
- Effects of lnterleukin-3 and lnterleuki-6 on Peripheral Blood Cells from Multiple Myeloma Patients and Their Clinical SignificanceActa Haematologica, 1992
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Plasma cell leukemia: A report on 15 patientsEuropean Journal of Haematology, 1989
- Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myelomaBlood, 1989
- Plasma cell myeloma--new biological insights and advances in therapyBlood, 1989
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975